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crobial resistance. National commitment to understand and address the problem is prerequi-
site. We analyzed and reviewed the antibiotic resistance related policies in Taiwan, USA,
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resistance management strategies, surveillance of HAI and antimicrobial resistance, conduct-
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system. No action today, no cure tomorrow. Taiwan CDC would take a multifaceted,
evidence-based approach and make every effort to combat antimicrobial resistance with
stakeholders to limit the spread of multi-drug resistant strains and to reduce the generation
of antibiotic resistant bacteria in Taiwan.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Multi-drug-resistant organisms (MDROs) are increasingly
being recognized as a global public health issue.1,2 The
World Health Organization (WHO) chose antimicrobial
resistance as its theme for World Health Day, April 7, 2011.3
WHO strongly recommends that governments implement
antibiotic stewardship programs for the containment of
antimicrobial resistance.4
Healthcare-associated infection and
antimicrobial resistance in Taiwan
Healthcare-associated infection (HAI) and antimicrobial
resistance are current challenges to the treatment of
infectious diseases in Taiwan.5e11 Taiwan nosocomial infec-
tion surveillance system (TNIS),12 a nationwide surveillance
study on the incidence and prevalence of HAI and antimi-
crobial resistance in Taiwan during 2003e2010,13 reported
that the HAI incidence rates (number of HAIs/number of
patient-days  1000%) in the intensive care units (ICUs) of
medical centers and regional hospitals has decreased
significantly from 12.8% to 8.2% (P Z 0.002) (Fig. 1A). HAI
incidence rates in medical centers and regional hospitals
decreased significantly from 4.1% to 2.7% (P Z 0.003)
(Fig. 1B). The proportion of site-specific HAIs in ICUs ande rates of healthcare-associate
nnual trends in the rates of he
Taiwan Nosocomial Infection Suregional hospitals are shown in Fig. 2A and Fig. 2B,
respectively. In 2010, blood stream infections topped the
list in the ICUs of medical centers, followed by urinary tract
infections and pneumonia. Urinary tract infections topped
the list in the ICUs of regional hospitals, followed by
bloodstream infections and pneumonia in 2010. The
proportion of blood stream infections increased signifi-
cantly in the ICUs of medical centers (p < 0.0001) and
regional hospitals (p Z 0.0039) during 2003e2010. The
common pathogens associated with HAIs in these ICUs are
shown in Table 1A and B. In 2010, the top three pathogens in
the ICUs were Candida species, Acinetobacter baumannii,
and Pseudomonas aeruginosa in medical centers; A bau-
mannii, Candida species, and Klebsiella pneumoniae were
the most common in regional hospitals. In the ICUs
of medical centers and regional hospitals in 2010, the
proportion of methicillin resistance in Staphylococcus
aureus (MRSA) isolates was 76.6%, vancomycin resistance in
enterococcal isolates (VRE) was 20.2%, imipenem or mer-
openem resistance in A baumannii isolates (carbapenem-
resistant A baumannii; CRAB) was 70.1%, imipenem or
meropenem resistance in P aeruginosa isolates (carbape-
nem-resistant P aeruginosa; CRPA) was 19.0%, carbapenem
resistance in Enterobacteriaceae isolates (CRE) was 5.0%,
carbapenem resistance in E coli isolates (CREC) was 2.2%,
and carbapenem resistance in K pneumoniae isolates
(CRKP) was 8.7%.d infection in the intensive care units of medical centers and
althcare-associated infection in medical centers and regional
rveillance System, 2003e2010.
Figure 2. (A) Proportion of site-specific healthcare-associated infections in the intensive care units of medical centers in Taiwan.
(B) The proportion of site-specific healthcare-associated infections in the intensive care units of regional hospitals in Taiwan. Data
from the Taiwan Nosocomial Infection Surveillance System, 2003e2010. SSI, surgical site infection; PNEU, pneumonia; BSI, blood
stream infection; UTI, urinary tract infection.
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Antimicrobial stewardship programs (ASPs) have the poten-
tial to reduce antimicrobial resistance, healthcare costs,
and drug-related adverse events by improving clinical out-
comes.14e16 During 1988e2001, New York Hospital Queens
has taken a series of management steps to address antimi-
crobial resistance, including monitoring ceftazidime and
imipenem resistance in Gram-negative bacteria, providing
infectious disease consultation and health education, and
limiting the use of cephalosporins and cephamycins. This
resulted in an 80% reduction in the use of cephalosporin-
cephamycin, 44% reduction in Klebsiella species isolates
resistant to ceftazidime, and 87% reduction in a surgical
ICU.17 Drew et al reported a reduction in the use of antibi-
otics at Chandler Medical Center in Kentucky after per-
forming a prospective audit with intervention and
feedback.18 They also reported a 30% reduction in the cost
of antimicrobials. Furthermore, formulary restriction and
the preauthorization of prescriptions have significantly
reduced the use of antibiotics and medical costs at Chandler
Medical Center since 1991, reduced the use of ceftazidime,
cefotaxime, and ceftriaxone by 80% in 2002, and also
decreased the resistant rates of several important patho-
gens, including multidrug-resistant P aeruginosa and MRSA.
ASP in Taiwan
Based on the abovementioned studies, ASPs are considered
to have significant and supporting scientific evidence. Tai-
wan’s ASP, in reference to the Infectious Diseases Society of
America (IDSA), Society for Healthcare Epidemiology of
America (SHEA) guidelines (a hospital pharmacy guide), and
WHO’s global strategy for the containment of antimicrobial
resistance to ASPs,3,4,19,20 has adopted scientific approaches
and emphasizes the impact of resistance to antimicrobial
agents. These approaches include the appropriate selection
of dosage, route of administration, and duration of anti-
microbial therapy. The objectives of ASP in Taiwan are to
strengthen the monitoring and surveillance systems usedto prevent the spread of antimicrobial-resistant bacteria,
maximize favorable outcomes, and minimize antimicrobial
resistance after antibiotic use. Regarding patient safety
concerns, Taiwan’s ASP combines hospital infection control
measures, such as hand hygiene and care bundles, that
might control the emergence and spread of antimicrobial
resistance. Taiwan’s ASP operates as follows (Table 2).
Establishment of national inter-sectoral
antimicrobial stewardship task force3,4
The implementation of a government’s health policy and
healthcare system is a key element to determining the
efficiency of interventions. Also, national commitment and
problem-solving skills are thought to be essential. To reduce
antimicrobial-resistant bacteria and lower the occurrence
of healthcare-associated infections, the Centers for Disease
Control, R.O.C (Taiwan CDC) has put a lot of effort into
making the containment of drug resistance a national
priority. As a result, the national inter-sectoral antimicro-
bial stewardship task force was established that included
physicians, infection control professionals, clinical micro-
biologists, information system specialists, nurses, clinical
pharmacists, healthcare professionals, veterinarians, agri-
culturalists, pharmaceutical manufacturers, government
representatives, media representatives, consumers, and
other stakeholders. The aims of the task force were to
increase the recognition of antimicrobial resistance, to
reduce the inappropriate spread of antimicrobial-resistant
bacteria, to establish a well-organized data-collection
process, to facilitate the implementation of interventions
such as education and surveillance, to develop indicators to
assess the impact of drug-resistance policies, to reduce
unnecessary medical costs, and to improve the quality of the
medical services provided.
Antimicrobial-resistance management strategies
The core management strategies against antimicrobial
resistance include the development of an effective health
Table 1 Distribution and rank order of selected pathogens associated with healthcare-associated infections in the (A)
intensive care units of medical centers and (B) regional hospitals in Taiwan. Data from the Taiwan Nosocomial Infection
Surveillance System, 2003e2010
Pathogens 2003 2004 2005 2006 2007 2008 2009 2010
Rank No. Rank No. Rank No. Rank No. Rank No. Rank No. Rank No. Rank No.
A
Pseudomonas aeruginosa 2 841 1 725 1 657 1 633 3 903 3 1017 3 914 3 753
Acinetobacter baumannii 3 776 3 625 2 535 3 499 2 944 2 1,148 2 1021 2 843
Candida species 8 255 8 236 7 237 5 475 1 1021 1 1529 1 1586 1 1128
C. albicans 200 188 192 339 678 1,024 989 701
Other Candida
spp. or NOSa
55 48 45 137 343 505 597 427
Escherichia coli 4 569 4 512 3 526 2 550 4 819 4 898 4 884 4 656
Staphylococcus aureus 1 855 2 656 4 521 6 468 6 685 5 849 7 561 7 469
Klebsiella pneumoniae 5 439 5 468 5 448 4 479 5 696 6 747 5 698 5 537
Enterobacter species 6 348 6 316 6 242 9 221 8 411 8 529 8 498 8 379
E cloacae 273 254 187 177 335 419 402 292
Other Enterobacter
spp. or NOSa
75 62 55 44 76 110 96 87
Yeast-like 10 181 9 200 9 158 7 253 7 564 7 647 6 669 6 505
Coagulase-negative
staphylococci
7 271 7 270 8 225 8 250 9 360 9 512 9 364 9 348
Stenotrophomonas
maltophilia
9 195 10 159 10 155 10 123 10 182 10 236 10 215 10 227
Other 1284 1249 1008 1110 1742 2373 2450 1999
Total 6014 5416 4712 5062 8327 10,485 9860 7844
B
Pseudomonas aeruginosa 1 810 1 822 1 725 1 570 1 811 2 832 4 702 4 757
Acinetobacter baumannii 3 627 2 675 3 575 4 467 2 760 1 838 1 821 1 1,003
Escherichia coli 4 547 4 622 2 581 3 486 5 673 4 758 3 729 5 741
Klebsiella pneumoniae 5 522 5 618 4 559 2 501 4 683 5 735 5 700 3 793
Staphylococcus aureus 2 721 3 660 5 515 5 407 6 554 6 579 6 521 6 504
Candida species 11 116 10 139 9 129 6 214 3 697 3. 816 2 770 2 933
C albicans 82 115 96 175 531 600 547 648
Other Candida
spp. or NOSa
34 24 33 39 166 216 223 285
Enterobacter species 6 285 6 255 6 260 7 181 7 273 7 308 7 298 8 297
E cloacae 187 183 191 132 198 235 227 220
Other Enterobacter
spp. or NOSa
98 72 69 49 75 73 71 77
Coagulase-negative
staphylococci
7 228 7 214 7 205 8 143 8 271 8 297 8 275 7 354
Proteus species 8 149 8 152 8 149 9 120 12 150 10 185 11 149 10 168
Proteus mirabilis 143 143 140 115 138 170 139 156
Other Proteus
spp. or NOSa
6 9 9 5 12 15 10 12
Yeast-like 12 54 12 68 12 79 10 119 9 267 9 256 9 246 9 230
Other 1173 1183 1086 859 1417 1470 1426 1649
Total 5232 5408 4863 4067 6556 7074 6637 7429
a NOS, not otherwise specified.
82 S.-H. Tseng et al.information system, prospective audits of the intervention
systems used, feedback, formulary restriction, preauthori-
zation, and the development of a computer management
system. An effective health information system can result in
reduced antimicrobial resistance. Taiwan CDC encourages
hospitals to establish an effective health information system
for prospective audits of direct intervention and feedback tothe prescriber. An effective health information system
includes the mechanisms and functions of surveillance, can
investigate the use of antibiotics, perform internal audits,
evaluate antimicrobial agents, deal with inappropriate
orders, and suggest alternative therapies. The prescribing
physicians will be contacted if their orders are evaluated as
inappropriate. Feedback might be provided as a verbal or
Antimicrobial stewardship program in Taiwan 83written notice.18e20 The results of surveillance should be
immediately reported back to clinicians so they can revise
drug use. Formulary restriction, preauthorization, and
computer management system requirements involve the
development of a thorough computer management system,
restricting the use of some particular antimicrobial agents to
specific indications, periods of therapy, disease severity,
physician services, prescribers, or patient populations. The
features of this restriction depend on certain factors, such as
institutional antimicrobial resistance and patient safety
issues related to the antimicrobial agents in ques-
tion.15,19,21,22 The prospective audit with intervention and
feedback, as well as the formulary restrictions and pre-
authorizations given to certain prescriptions by infection
control physicians and clinical pharmacists with infectious
disease training, can reduce inappropriate antibiotic use
and additional medical costs by implementing antibiotic-
management programs.20 In order to urge hospitals to
develop and implement strategies that address antibiotic
control, Taiwan CDC has implemented a “core management
strategy of antibiotic resistance” through audit mecha-
nisms of hospital accreditation,23 infection control
inspection,24 and the national health insurance paymentTable 2 Antimicrobial stewardship program in Taiwan
1. Establish a national inter-sectoral antimicrobial stewardship
2. Antimicrobial-resistance management strategies
2.1. Core antimicrobial-resistance management strategies
2.1.1. Effective health information system, prospective audi
2.1.2. Formulary restriction, preauthorization and computer
2.2. Supplemental antimicrobial-resistance management strate
2.2.1. Education, guidelines and clinical pathways
2.2.2. Computer physician-order entry and antimicrobial ord
2.2.3. Streamlining or de-emphasis of empirical antimicrobia
2.2.4. Computer decision-support system and optimization o
2.2.5. Pharmacokinetic and pharmacodynamic characteristic
3. Surveillance of HAI and antimicrobial resistance
3.1. Taiwan CDC’s infectious disease reporting system
3.2. Taiwan nosocomial infection surveillance system (TNIS)
4. Hospital infection control
4.1. Promote hand hygiene
4.1.1. Hand hygiene demonstration centers (National Taiwan
Tri-service General Hospital)
4.1.2. Nationwide hand-hygiene certification and reward sys
4.2. Promotion of care bundle: multimodal infection control m
4.2.1. Central line-associated blood stream infections (CLAB
4.2.2. Catheter-related urinary infections (CAUTI) bundles
4.2.3. Ventilator-associated infections (VAP) bundles
4.2.4. Surgical site infection (SSI) bundles
4.2.5. Antibiotic care bundles
5. Regulation of pharmaceutical affairs and infection control
5.1. Pharmaceutical Affairs Act
5.2. Communicable Disease Control Act
5.3. Regulation of the implementation and inspection of infect
6. Evaluation and audit mechanisms
6.1. Hospital accreditation system
6.2. Hospital inspection system
6.3. National health insurance payment systemsystem.25 In relation to the standard criteria of hospital
accreditation and hospital infection control inspections,
standard criteria related to antibiotic management are
shown in Table 3.Supplemental antimicrobial-resistance
management strategies
Supplemental strategies can play a crucial role in
ASPs.20,26 In order to lower the incidence of HAIs and
prevent the spread of antimicrobial resistance within
medical institutions, the following actions were listed as
supplemental antimicrobial-resistance strategies by
Taiwan CDC. These include preservice and in-service
education programs that present related knowledge
regarding the spread of multidrug-resistant microorgan-
isms and the multidisciplinary development of evidence-
based practice guidelines27,28 and clinical pathways,26,29
computerized physician-order entry, antimicrobial order
forms,30 real-time information systems, computerized
decision-support systems, the streamlining or de-emphasis
of empirical antimicrobial therapy based on culturetask force
t with intervention and feedback
management system
gies
er forms
l therapy
f antibiotics
s of the drugs
University Hospital, Kaohsiung Veterans General Hospital, and
tem
easures and intervention
SI)bundles
ion control measures in medical institutions
Table 3 Standard criteria related to antibiotic management of hospital accreditation and hospital infection control
inspections
1. Hospital should have antibiotic-resistance control measures.
1.1. Hospital should have effective antibiotics control through educational and administrative means:
1.1.1. Hospital should conduct a course on the “appropriate use of antibiotics” at least once every 6 months, and clinicians
should attend the course at least once per year.
1.1.2. Hospitals should edit the control measures for antibiotic use so that physicians can search for the appropriate use of
antibiotics at any time.
1.1.3. A monitoring mechanism should be set up for all types of antibiotic use in the hospital.
1.1.4. Implement reasonable usage of nonrestrictive antibiotics in the hospital. Hospital inspectors should review the
medical records at random, the use of nonrestrictive antibiotics should be listed in the medical records, and none of
the following circumstances should appear:
(1) Continuous use of first line of narrow-spectrum antibiotics with inappropriate reasons in patients with severe
illness with multiorgan dysfunction or infection, transfer to the hospital after ineffective treatment at other
hospitals, and circumstances such as hospital-acquired pneumonia or immune deficiency.
(2) Continued use of first-line narrow-spectrum antibiotics with irrational reasons after ineffective use of first-line
narrow-spectrum antibiotics for 3 days.
(3) Not selecting the appropriate antibiotics based on the site of infection, such as intra-abdominal anaerobic
bacteria.
(4) Use of ineffective treatment for community-acquired infection without rational reasons.
(5) Doses are given without considering the patient’s weight and liver and kidney functions.
1.1.5. Reasonable use of restricted antibiotics. Hospital inspectors should review the medical records at random, and the
use of restrictive antibiotics should be listed in the medical records without any of the following circumstances.
(1) Use of broad-spectrum antibiotics for irrational reasons when the clinical status is listed as mild or if there are no
symptoms.
(2) Use three or more antibiotics at the same time for an irrational reason.
(3) The given drug types do not meet the national or international guidelines for antibiotics treatment.
(4) Doses are given without considering the patient’s weight and liver and kidney functions.
1.1.6. Review all of the uses of restrictive antibiotics.
1.1.7. Correctly analyze and improve any mistakes by reviewing the involved mechanisms.
1.1.8. Hospitals should set up an information system for checking antibiotic use and implement a reminder mechanism that
is activated when prescribing antibiotics.
1.1.9. Correctly execute and analyze the conditions that do not meet the regulated uses of antibiotics and to propose
improvement measures.
1.1.10. Lower the inappropriate use of antibiotics.
2. Correct use of prophylactic antibiotics in hospitals.
Use of prophylactic antibiotics should be listed in the medical record, and hospital inspectors should review the medical
records at random.
2.1. The first dose of the prophylactic antibiotic should be given within 1 hour before the surgical incision if the use of
prophylactic antibiotic is required (e.g., for cesarean section, prophylactic antibiotics should be given immediately after
umbilical ligation excision).
2.2. Drug selection should be consistent with the guidelines for antibiotic use in Taiwan.
2.3. The antibiotic dose should be consistent with the patient’s weight.
2.4. Additional antibiotics should be given as necessary during a surgery (with consideration of the pharmacokinetics).
2.5. Discontinue the use of antibiotics after clean surgery. Antibiotics should be used for less than 24 hours after major
surgery.
2.6. Set up monitoring and improve the mechanisms for the effective use of prophylactic antibiotics.
3. Reasonable antibiotics use in outpatients.
Hospital inspectors should review the medical records at random.
3.1. Use antibiotics only if it is required. Detailed explanations should be written on the medical record when using
antibiotics.
3.2. Antibiotics cannot be used for treating the common cold.
3.3. Rational use of the types and dosages of antibiotics with consideration of the patient’s weight and kidney functions.
3.4. Use antibiotics for a rational period of time. Detailed explanations should be written to explain any irregularities.
3.5. Monitoring and improve the mechanisms for the effective use of antibiotics in outpatients.
4. Effective management and reporting of multi-drug resistance bacteria in hospitals.
4.1. Based on the bacterial isolate and the type of ward, responsible infection control staff, clinicians, and nurses can control
the isolates, especially antimicrobial-resistant bacteria such as CRAB, VRE, MRSA, and CRE. Analytical reports should
include the isolated strain and antibiotic sensitivity.
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4.2. Reports on antibiotic susceptibility of clinically isolated strains should be edited annually. The latest statistical reports
should be distributed to every physician or announced through the internet in order to allow physicians to check these
reports at any time.
4.3. Consideration of patient privacy, mark and proper isolation should effectively be done for those with specific
antimicrobial resistant infection or colonization.
4.4. Statistical reports regarding bacterial isolates of HAI should be performed at least every 6 months. These should be
distributed to physicians and related staff or be made public through the internet.
4.5. Strains, isolates, and analytical reports on inpatients should be provided to healthcare staff as reference.
4.6. Multidrug resistant-related data should be reported to Taiwan CDC per their policy.
4.7. Set up relative mechanisms and make sure each physician understands related information.
4.8. Analyze the trends in antimicrobial resistance and antibiotic use every 6 months.
4.9. Based on the report, related policies should be implemented to improve the control of VRE, MRSA, CRAB, CRE, and
others.
Antimicrobial stewardship program in Taiwan 85results, the elimination of redundant combination thera-
pies,31,32 optimization of antimicrobial dosing based on
individual patient characteristics, causative organism, site
of infection, pharmacokinetic and pharmacodynamic char-
acteristics of the drug, and a systemic plan for parenteral to
oral conversion of antimicrobials.33,34 Besides, these were
incorporated into the standard criteria of hospital accredi-
tation, hospital infection control inspection, as well as audits
of national health insurance payments. The aim is to
supervise and urge hospitals to establish appropriate mech-
anism for antibiotic use with effective implementation.
Surveillance of HAI and antimicrobial resistance
The surveillance of antimicrobial resistance is fundamental
to the effective implementation of any strategy for the
containment of antimicrobial resistance because it is the
means by which physicians can monitor the efficacy of
various interventions. Taiwan CDC established TNIS to
monitor HAI and antimicrobial resistance. Taiwan CDC
adopted voluntary participation, in reference to the
HAI surveillance mechanism of Europe35 and USA.36 This
surveillance mechanism has been extended to all levels of
hospitals since the ICUs of medical centers began to report
their findings at the end of 2001. In order to understand the
trends of multidrug-resistant strains, Taiwan CDC under-
took the monitoring of HAI and antimicrobial resistance.
The current TNIS has enrolled more than 300 hospitals, of
which more than 70 hospitals report cases through an
information exchange center.12 This surveillance system,
which utilizes standard tables for data analysis, can report
back to individual hospitals their own analysis tables
on HAI, antimicrobial resistance, the distribution of path-
ogens, and antibiotic resistance. In order to analyze,
interpret, and apply the HAI and antimicrobial resistance
data, the HAI and antimicrobial-resistance data-analysis
task force under Taiwan’s Healthcare Infection Control
Practices Advisory Committee (Fig. 3) was set up and the
results of the analysis were distributed to hospitals for
reference and other documents, journals, and reference
channels were provided. The feedback mechanisms of
the regular data analysis provide self-monitoring within the
hospitals and reference to hospitals at the same level. The
committee will also continue to review and improve the
surveillance reporting system in order to improve datavalidation, accuracy, and completeness, which should help
both the government and the hospitals effectively use the
national surveillance data.
Control of hospital infections
Poor compliance with infection control measures in any
setting can greatly increase the spread of drug-resistant
bacteria, especially during outbreaks. Collaboration
between the ASP and hospital infection control programs is
essential.4,22,37 The combination of effective antimicrobial
stewardship with a comprehensive infection control
program has been shown to limit the emergence and
transmission of antimicrobial-resistant bacteria.38 The
following actions were listed as the main strategies for
infection control by Taiwan CDC: to promote hand hygiene
in healthcare facilities39 and communities; to conduct
a project entitled “care bundle to lower HAIs”; to establish
guidelines40 for infection control measures and contact
precautions40; to strengthen aseptic practices, steriliza-
tion, and disinfection41; to promote environmentally
friendly hygiene and waste management procedures; and
to facilitate environmental designs for appropriate infec-
tion control practices.42 Among those strategies, continuing
to promote hand hygiene in healthcare facilities and
communities and conducting a project entitled “care
bundle to lower the HAIs” are two of the top priorities of
Taiwan CDC. These initiatives are described below.
Promotion of hand hygiene
Ensuring good hand hygiene is key to preventing the spread
of infections and bringing disease outbreaks under
control.43,44 In order to effectively prevent HAIs, a theme
promoting hand hygiene was planned based on the “Clean
Care is Safer Care” initiative of Patient Safety Alliance
(WHO).45 Three medical centers (National Taiwan Univer-
sity Hospital, Kaohsiung Veterans General Hospital, and
Tri-service General Hospital) were chosen as hand-hygiene
demonstration centers by Taiwan CDC. The goal is to ach-
ieve hospital-wide participation, including involvement at
the management level and patient participation. At the
same time, the culture of patient safety was formed
through the creation of a nationwide hand-hygiene certifi-
cation and reward system that might increase the
Figure 3. Taiwan’s Healthcare Infection Control Practices Advisory Committee.
86 S.-H. Tseng et al.accessibility of hand-hygiene equipment and hand-hygiene
recognition by healthcare workers. Furthermore, contin-
uous hospital quality improvements and effective imple-
mentation of hand hygiene can be encouraged through
assessment, performance indicators, and audit mechanisms
of both the hospital accreditation process and hospital
infection inspections.
Promotion of care bundle: multimodal infection
control measures and interventions
HAIs are the leading causes of death in the USA, accounting
for an estimated 1.7 million infections, 99,000 associated
deaths, and an estimated $28e33 billion in additional
healthcare costs in 2002. Four categories of infections,
including surgical site infections (SSI), central line-
associated bloodstream infections (CLABSI), ventilator-
associated pneumonia (VAP), and catheter-associated
urinary tract infections (CAUTI), account for approxi-
mately three quarters of HAIs that present in the acute care
hospital setting. Currently, CAUTI comprise the highest
percentage (34%) of HAIs, followed by SSI (17%), CLABSI
(14%), and VAP (13%) in the USA.46e49 Many of these HAIs
can be prevented through increased awareness and imple-
mentation of recommended infection control practices. A
“care bundle” is a group of interventions related to
a disease process that, when executed together, results in
better outcomes than when implemented individually. The
individual bundle elements are built upon evidence-based
practices.46e52 In recent years, large-scale regional andstatewide projects, such as the Pittsburgh Regional
Healthcare Initiative and the Michigan Keystone Project,
have demonstrated roughly 70% reductions in CLABSI rates
in ICUs by increasing adherence to the recommended care
bundle for the insertion of central lines.47,50 Taiwan CDC
promotes a care bundle that includes CLABSI bundles,53
CAUTI bundles,54 VAP bundles,55 SSI bundles56, and antibi-
otic care bundles for lowering multidrug resistant bacteria
infections, such as MRSA, VRE, and CRAB.
Pharmaceutical affairs and infection control
regulations
The Pharmaceutical Affairs Act was amended in 2005 by
the Taiwan Food and Drug and Administration (TFDA),57
and this act clearly attempts to regulate the sale, supply,
and dispensing of prescriptions in order to ensure that
antimicrobials meet the international standards of quality,
safety and efficacy. The Communicable Disease Control
Act, which was amended in January 2004, clearly states
that medical institutions should prevent the occurrence of
HAI.57,58 In November 2004, the “regulation for communi-
cable disease control and vaccination measures in health/
medical institutions” was promulgated. In January 2008,
the title was amended as the “implementation and
inspection of infection control measures for medical
institutions,” and the amended document clearly indicates
that medical institutions should implement infection
control measures and standard items for inspection by
competent authority.
Antimicrobial stewardship program in Taiwan 87Audit mechanism of hospital accreditation,
inspection, and national health insurance
payment system
The existence of appropriate legislation regarding antimi-
crobial agents and infection control cannot improve the
quality of infection control and use of antibiotics unless
enforced. To reduce HAIs and antimicrobial resistance, the
standard criteria for hospital infection control inspection
have been published by the central health authority every
year since 2005, and a local health officer is responsible for
the inspection of hospitals within each area. Improvements
have been made to the hospital infection control program
since 2008; infection control experts were allocated to
assist local health officers and evaluate the infection
control practices. This program involves the integration of
standard criteria for hospital infection control inspection
and hospital infection control accreditation and the
establishment of a fair audit mechanism. The latter
includes the results of hospital infection control inspections
into hospital infection control accreditation and national
health insurance payment system as references. In 2011,
there were a total of 10 items and 31 secondary items listed
in the standards for infection control inspection.
HAIs and antimicrobial resistance are two of the most
preventable leading causes of mortality. These infections
also add a significant economic burden to the healthcare
system. Taiwan CDC is responsible for supervising medical
institutions and establishing a robust and organized infec-
tion control framework. Potential measurements include,
for example, the application of healthcare information
technology to antimicrobial stewardship, establishment of
infection control committees and dedicated units, and the
allocation of physicians and nurses to address infection
control, antibiotic regulations, and the promotion of these
practices.
Taiwan CDC, in conjunction with infectious diseases
physicians, infectious control experts, and other multidis-
ciplinary experts, conducts antimicrobial stewardship and
infection control programs through the audit mechanisms
of hospital accreditation, hospital inspection, and the
national health insurance payment system to reduce,
prevent, and eventually eliminate most of the significant
burden to our national health system. The Taiwanese
government also encourages drug development programs to
foster the innovation, research, and development of new
tools that work to reduce the financial incentives that
encourage the irrational use of medicine, i.e., “No action
today, no cure tomorrow.” Taiwan CDC makes every effort
to combat antimicrobial resistance by targeting consumers,
prescribers, dispensers, veterinarians, managers of hospi-
tals and diagnostic laboratories, patients and visitors to
healthcare facilities, as well as national governments, the
pharmaceutical industry, professional societies, and inter-
national agencies.3,4
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